Emcure Pharma IPO GMP, Review, Price, Allotment

Emcure Pharma IPO description – Emcure is a leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. It is ranked as (i) the 12th largest pharmaceutical company in India and (ii) the largest pharmaceutical company in India in the gynecology, blood related and HIV antivirals therapeutic areas, based on sales in India in the FY2021. It is an R&D driven company with a differentiated product portfolio that includes orals, injectables and biologics, as well as an mRNA platform through which it is currently developing a COVID-19 vaccine.

Emcure’s products are sold across over 70 countries with a strong presence in Europe and Canada. The company has experienced rapid growth in recent years and it is one of the fastest growing pharmaceutical companies in India. Between the FY2019 and the FY2021, its total sales in India grew at a CAGR of 11.28% from INR32,856 million to INR40,686 million, outperforming the Indian pharmaceutical industry’s overall growth in sales in India, which grew at a CAGR of 5.78%.

The company is present in most of the major therapeutic areas, including, gynecology, cardiovascular, vitamins, minerals and nutrients, oncology/anti-neoplastic, HIV and blood-related. Across all such therapeutic areas, it is ranked among the top 10 pharmaceutical companies in India in terms of sales in India in the FY2021.

Promoters of Emcure Pharma – Satish Mehta and Sunil Mehta

---

Emcure Pharma IPO Details

Subscription Dates	Coming soon
Price Band	INR – per share
Fresh issue	INR1,100 crore
Offer For Sale	18,168,356 shares
Total IPO size	Coming soon
Minimum bid (lot size)	Coming soon
Face Value	INR 10 per share
Retail Allocation	35%
Listing On	NSE, BSE

---

Emcure Pharma’s Financial Performance

	FY2019	FY2020	FY2021
Revenue	4,815.6	5,130.9	6,091.8
Expenses	4,469.5	4,922.1	5,345.9
Net income	236.8	134.5	418.6
Margin (%)	4.9	2.6	6.9

---

Emcure Pharma IPO News

• Emcure IPO RHP
• Emcure IPO DRHP

---

Emcure Pharma Valuations & Margins

	FY2019	FY2020	FY2021
EPS	10.47	4.62	21.68
PE ratio	–	–	NA
RONW (%)	10.35	4.37	17.25
ROCE (%)	14.85	11.67	22.64
EBITDA (%)	18.32	15.32	20.80
Debt/Equity	–	–	–
NAV	101.15	105.72	125.68

---

Emcure Pharma IPO GMP Daily Trend

Date	Emcure Pharma IPO GMP	Kostak	Subject to Sauda

---

Emcure Pharma IPO Subscription – Live Updates

Category	Shares Offered	Day 1	Day 2	Day 3
QIB
NII
Retail
Employees
Total

---

Emcure Pharma IPO Reviews – Subscribe or Avoid?

Angel One –
Arihant Capital –
Ashika Research –
Asit C Mehta –
BP Wealth –
Canara Bank Securities –
Choice Broking –
Elite Wealth –
GEPL Capital –
Hem Securities –
ICICIdirect –
KR Choksey –
Marwadi Financial Services –
Motilal Oswal –
Nirmal Bang –
Religare Broking –
Samco Securities –
SMC Global –
Ventura Securities –

---

Emcure Pharma Offer Registrar

Link Intime India Private Limited 
C-101, 1st Floor,
247 Park, Lal Bahadur Shastri Marg,
Vikhroli (West), Mumbai 400 083,
Maharashtra, India
Phone: +91 22 4918 6200
Fax: +91 22 4918 6195
Email: [email protected]
Website: www.linkintime.co.in

---

Emcure Pharma Contact Details

Emcure Pharmaceuticals Limited
14th Floor, Tower 3, Plot No. P2, IT-BT Park
Phase II, M.I.D.C., Hinjawadi,
Pune – 411057,
Maharashtra, India
Phone: +91 22 7181 8181
Email: [email protected]
Website: www.emcure.com

---

Emcure Pharma IPO Allotment Status

Emcure Pharma IPO allotment will be available on Link Intime’s website. Click on this link to get allotment status.

---

Emcure Pharma IPO Timetable

IPO Opening Date	Coming soon
IPO Closing Date	Coming soon
Finalisation of Basis of Allotment	Coming soon
Initiation of refunds	Coming soon
Transfer of shares to demat accounts	Coming soon
Listing Date	Coming soon
Opening Price on NSE	Coming soon
Closing Price on NSE	Coming soon

---

Emcure IPO FAQs